Formats
  1. Journal Article (66987)
  2. Meeting Abstract (33621)
  3. Book Section (5116)
  4. Review (3796)
  5. Editorial (2199)
  6. Conference Paper (1527)
  7. Correspondence (670)
  8. Guidelines (668)
  9. Research Letter (555)
  10. Book Whole (345)
  11. Miscellaneous (340)
Groups
  1. Department of Medicine (39140)
  2. GSK Faculty (22507)
  3. Solid Tumor Oncology Division (22124)
  4. Surgery (21323)
  5. Survivorship Research (15803)
  6. Sloan Kettering Institute Faculty (15667)

More Groups

People
  1. Marc Ladanyi (1329)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1053)

More People

Years
  1. 2026 (1)
  2. 2025 (2355)
  3. 2024 (5382)
  4. 2023 (5808)
  5. 2022 (6169)
  6. 2021 (5721)

More Years

Publications
  1. Journal of Clinical Oncology (8596)
  2. Blood (4954)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2615)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13871)
  2. American Society of Clinical Oncology (9181)
  3. Springer (7204)
  4. Nature Publishing Group (6393)
  5. American Association for Cancer Research (6016)
  6. Elsevier Science, Inc. (5529)

More Publishers

Results (115824)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying germline genetic alterations or environmental factors associated with bilateral germ cell tumor (GCT)
    Meeting Abstract

    Gleeson, J. P.; Harrold, E.; Bromberg, M.; Patel, Z.; Knezevic, A.; Thomas, T.; Ravichandran, V.; Tran, C.; Silber, D.; Carver, B. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+cancers
    Meeting Abstract

    Fu, S.; Nabell, L.; Pearson, A. T.; Leidner, R.; Adkins, D.; Posner, M. R.; Nieva, J. J.; Richardson, D. L.; Pimentel, A.; Goel, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Stereotactic radiosurgery (SRS) versus whole brain radiation therapy (WBRT) in patients with small cell lung cancer (SCLC) and intracranial metastatic disease (IMD): A systematic review and meta-analysis
    Meeting Abstract

    Gaebe, K.; Li, A. Y.; Park, A.; Parmar, A.; Lok, B. H.; Sahgal, A.; Chan, K. K.; Erickson, A. W.; Das, S.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702)
    Meeting Abstract

    Ganti, A. K.; Dueck, A. C.; Fruth, B.; Rimner, A.; Waqar, S. N.; Mix, M. D.; Petty, W. J.; Bogart, J. A.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase I study of entinostat (Ent), atezolizumab (A), carboplatin (C), and etoposide (E) in previously untreated extensive-stage small cell lung cancer (ES-SCLC), ETCTN 10399
    Meeting Abstract

    Gentzler, R. D.; Piekarz, R.; Villaruz, L. C.; Rhee, J. C.; Lai, W. C. V.; Horton, B.; Mock, J.; Hanley, M.; Rudek, M. A.; Phelps, M. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Clinical characteristics and molecular features of non-small cell lung cancers (NSCLCs) following disease progression on immune checkpoint inhibitors (ICIs)
    Meeting Abstract

    Gainor, J. F.; Ravi, A.; Awad, M. M.; Holton, M.; Arniella, M.; Stewart, C.; Freeman, S.; Leshchiner, I.; Chow, A.; Henick, B. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Progression-free survival after second line of therapy (PFS-2) for metastatic clear cell renal cell carcinoma (ccRCC) in patients treated with first-line immunotherapy combinations
    Meeting Abstract

    Fitzgerald, K. N.; Duzgol, C.; Knezevic, A.; Shapnik, N.; Kotecha, R.; Aggen, D. H.; Carlo, M. I.; Shah, N. J.; Voss, M. H.; Feldman, D. R.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • DREAM3R: Durvalumab with chemotherapy as first-line treatment in advanced pleural mesothelioma-A phase 3 randomized trial
    Meeting Abstract

    Forde, P. M.; Nowak, A. K.; Kok, P. S.; Brown, C.; Sun, Z.; Anagnostou, V.; O'Byrne, K. J.; Yip, S.; Cook, A.; Lesterhuis, W. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Dysfunctional CD8+T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC)
    Meeting Abstract

    Friedman, C. F.; Zhou, Q.; Iasonos, A.; Holland, A.; Ramirez, L.; Grisham, R. N.; Guo, R.; Lichtman, S. M.; Kyi, C.; Makker, V.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Multicenter phase 2 trial of the PARP inhibitor (PARPi) olaparib in recurrent IDH1 and IDH2-mutant contrast-enhancing glioma
    Meeting Abstract

    Fanucci, K.; Pilat, M. J. P.; Shah, R.; Boerner, S. A.; Li, J.; Durecki, D. E.; Drappatz, J.; Collichio, F. A.; Puduvalli, V. K.; Lieberman, F. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save